Bavencio (avelumab) and Inlyta (axitinib) are recommended by NICE for the treatment of advanced renal cell carcinoma, available on the Cancer Drugs Fund.
List view / Grid view
Renal cell carcinoma
Filter the results
The National Institute for Health and Care Excellence (NICE) has stated that combined use of the drugs pembrolizumab and axitinib is not recommended for untreated advanced renal cell carcinoma in adults.